✦ LIBER ✦

839 TWELVE WEEKS OF TREATMENT IS INSUFFICIENT FOR HCV GENOTYPE 2 AND 3 INFECTED PATIENTS WITH STEATOSIS

✍ Scribed by J. Westin; M. Lagging; C. Pedersen; M. Rauning Buhl; M. Farkkila; N. Langeland; K. Morch; A. Alsio; G. Norkrans

Book ID: 117376765
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 73 KB
Volume: 48
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(08)60841-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBA

236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR

✍ L.E. Adinolfi; R. Zampino; B. Guerrera; L. Restivo; L. Rinaldi; A. Ciervo; V.R. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Steatosis is the predictor of relapse in

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR

✍ L. Restivo; R. Zampino; B. Guerrera; L. Ruggiero; L. E. Adinolfi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Treatment with pegylated interferon and

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

✍ Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

The aim of this study was to determine the efficacy of 14 weeks of treatment in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR). In a noncontrolled multicenter trial, 122 treatment-naive patients received 1.5 mug/kg pegylated interferon alf

Individualized treatment with combinatio

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3

✍ Alessandra Mangia; Franco Bandiera; Giuseppe Montalto; Leonardo Mottola; Valeria 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 687 KB

[604] COMPARISON OF A SHORTENED RIBAVIRI

[604] COMPARISON OF A SHORTENED RIBAVIRIN TREATMENT VS A 24 WEEK STANDARD COMBINATION THERAPY IN HCV INFECTED PATIENTS WITH GENOTYPE 2/3

✍ B. Kallinowski; K. Stein; W. Boecher; T. Goeser; U. Spengler; R. Link; H. Klinke 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 276 KB

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHO

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

✍ Kowdley, K.V.; Stuart, G.C.; Reddy, R.K.; Rossaro, L.; Bernstein, D.E.; An, D.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 172 KB